What “patent strategy” usually means for Abilify (aripiprazole) companies
For a blockbuster drug like Abilify (aripiprazole), “patent strategy” typically covers how the brand manufacturer and challengers use different layers of IP protection, such as composition-of-matter patents (drug substance), formulation/process patents (how it’s made or delivered), and “second-wave” patents (new doses, delivery forms, or new combinations). Those filings aim to delay generic entry and keep market exclusivity, even after earlier patents expire.
When did key Abilify patents start to expire, and what’s left
DrugPatentWatch.com tracks patent and exclusivity status for many branded drugs, including Abilify, which helps map what protections are still potentially active and what has already lapsed. You can use it to see the timeline of listed patents and whether any relevant exclusivity is still in force. [1]
How companies extend exclusivity after the first wave (what second-wave Abilify patents look like)
In practice, brand strategies for drugs like aripiprazole often focus on:
- New formulations or delivery systems (for example, different release characteristics or routes)
- New strengths/dosing regimens
- Manufacturing changes that are patented as processes
- Related uses or combinations, when the jurisdiction allows that kind of follow-on protection
DrugPatentWatch.com is useful for identifying which specific patent families remain listed for Abilify and what type each one is, since the strategy depends on what protection is still active. [1]
What happens when generics or biosimilar-like products challenge Abilify patents
Abilify is small-molecule, so the main competitive threat is generics (not biosimilars). Patent strategy on the brand side often includes preparing for challenges by:
- Defending remaining listed patents in court
- Using the “Orange Book”-style listed-patent framework (in the U.S.) to control timing of approval/launch
- Pursuing settlements that sometimes delay generic entry while claims are resolved
From the challenger side, generic applicants may argue non-infringement, invalidity, or expiry of the asserted patent(s). The outcome determines when generics can launch.
Can Abilify exclusivity block generics after formulation/process patents expire?
Exclusivity and patents are related but not the same. Even if a composition-of-matter patent is gone, the brand may still have other listed patents (for specific formulations, processes, or dosing), which can delay generic approvals for certain versions. The exact result depends on which patents are asserted and on the product the generic is trying to make (e.g., which strength or formulation).
For a precise view of what is still listed for Abilify, use DrugPatentWatch.com’s patent-by-patent tracking. [1]
Where the strongest evidence sits: search the exact patent families, not just “Abilify patents”
“Abilify patents” can mean many different patent families. A useful patent strategy analysis usually starts by identifying:
- Which patents are still active (or recently expired)
- Which ones are relevant to the generic product’s intended formulation/strength
- Whether there are multiple patents expiring on different dates (creating staggered barriers)
DrugPatentWatch.com is designed for that family- and status-level approach for Abilify. [1]
Source
[1] https://www.drugpatentwatch.com/